reports
Transactions in Connection with Share Buy-back Program
Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; May 21, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions were executed under the program from May 13, 2024 to May 17, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulated through last announcement 689,655 1,393,466,215.08May 13, 2024X...
Storaktionærmeddelelse – Direktør Svend Hornsylds Legat
Storaktionærmeddelelse – Direktør Svend Hornsylds Legat I henhold til § 30 i lov om kapitalmarkeder oplyses det hermed, at Direktør Svend Hornsylds Legat i henhold til § 38, stk. 1, i lov om kapitalmarkeder, har meddelt Aktieselskabet Schouw & Co., at Direktør Svend Hornsylds Legat den 17. maj 2024, som følge af den i Aktieselskabet Schouw & Co. gennemførte kapitalnedsættelse, har øget sin beholdning af aktier i selskabet til 15,12% af den samlede aktiekapital. Besiddelsen overstiger dermed 15%, jf. § 38 i lov om kapitalmarkeder. Aktieselskabet Schouw & Co. Jørgen Dencker...
Major shareholder announcement – Direktør Svend Hornsylds Legat
Major shareholder announcement – Direktør Svend Hornsylds Legat Pursuant to section 30 of the Danish Capital Markets Act, it is hereby announced that Direktør Svend Hornsylds Legat has notified Aktieselskabet Schouw & Co. pursuant to section 38(1) of the Danish Capital Markets Act that Direktør Svend Hornsylds Legat on 17 May 2024, as a result of the capital reduction carried out in Aktieselskabet Schouw & Co., increased its holding of treasury shares in the company to 15.12% of the total share capital. The holding thus exceeds 15%, cf. section 38 of the Danish Capital Markets Act. ...
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy ...
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics This regulatory clearance enables clinical development of SAB-142 in patients with type 1 diabetes in the US MIAMI, May 21, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), today announced that the U.S. Food and Drug Administration (FDA) has provided clearance for the Company’s investigational new drug (IND) application to proceed for its phase 1 clinical trial for type 1 diabetes (T1D) therapy SAB-142. SAB is a clinical-stage biopharmaceutical compan...
STLLR Gold Announces Exploration Drilling Results at the Tower Gold Pr...
Toronto, Ontario--(Newsfile Corp. - May 21, 2024) - STLLR Gold Inc. (TSX: STLR) (OTCQX: STLRF) (FSE: O9D) ("STLLR" or the "Company") announces the assay results from the exploration drilling of prospective targets near the 55 Zone and Westaway Deposits at the Golden Highway Area (western end) of the Tower Gold Project in Timmins, Ontario, Canada. Exploration drilling at the Colomac Gold Project in the Northwest Territories, Canada, has also commenced. Table 1: 2024 Exploration Drilling Highlights - 55 Zone West and Westaway South Limb Targets(See Figures 1-4):TargetsHole IDAssay Result55 Zone ...
Stellantis to Participate in Bernstein 40th Annual Strategic Decision...
Stellantis to Participate in Bernstein 40th Annual Strategic Decisions Conference Stellantis to Participate in Bernstein 40th Annual Strategic Decisions Conference AMSTERDAM, May 21, 2024 – Carlos Tavares, Stellantis Chief Executive Officer, will participate in a fireside chat on Wednesday, May 29, 2024, at 9:00 a.m. EDT / 3:00 p.m. CEST at the Bernstein 40th Annual Strategic Decisions Conference. To watch the live session, visit the following webcast link: Details for watching the fireside chat are also available under the section of the Stellantis corporate website. For those unab...
Munchener Ruckversicherungs-Gesellschaft AG: 1 director
A director at Munchener Ruckversicherungs-Gesellschaft AG bought 110 shares at 457.800EUR and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ove...
Jinyoung Co Ltd: 1 director
A director at Jinyoung Co Ltd sold 43,103 shares at 3,404.346KRW and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
Clearside Biomedical Announces Publication of Consensus Guidelines for...
Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS®) Injection in Leading Peer-Reviewed Industry Journal, RETINA® - Expert Panel of Ophthalmologists Developed Professional Guidelines in Using the Innovative Technique for Retinal Therapeutic Delivery - - Current Clinical Evidence and Physician Experience Support SCS Injection as a Safe and Effective Method for Delivering Retinal and Choroidal Therapeutics - ALPHARETTA, Ga., May 21, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical compan...
Xtract One Announces Fiscal 2024 Third Quarter Conference Call
Xtract One Announces Fiscal 2024 Third Quarter Conference Call TORONTO, May 21, 2024 (GLOBE NEWSWIRE) -- Xtract One Technologies Inc. (TSX: XTRA) (OTCQX: XTRAF) (FRA: 0PL) (“Xtract One” or the “Company”), a leading technology-driven threat detection and security solution that prioritizes the patron access experience by leveraging AI, today announced that it will release fiscal 2024 third quarter results after the close of trading on June 6, 2024. Peter Evans, Xtract One CEO and Director, and Karen Hersh, CFO and Corporate Secretary, will host a webcast and conference call at 10:00 a.m. Ea...
Copenhagen Capital A/S – Periodemeddelelse for 1. kvartal 2024
Copenhagen Capital A/S – Periodemeddelelse for 1. kvartal 2024 Copenhagen Capital A/S afgiver periodemeddelelse for 1. kvartal 2024. Selskabet offentliggør ikke finansiel information som en del af periodemeddelelser. Driften af ejendommene forløber som forventet. Selskabet har i perioden haft fortsat fokus på drift af porteføljen og tomgangen er lav. Selskabet er arbejder med projekteringen og indhentning af priser for tagboligprojektet på Ole Suhrs Gade 13-15, København K. Selskabet har i perioden tilbagekøbt de resterende 8.684.791 stk. 8% Præferenceaktier 2024. Aktierne ble...
BlackLine, Inc. Announces Proposed Private Offering of $500,000,000 of...
BlackLine, Inc. Announces Proposed Private Offering of $500,000,000 of Convertible Senior Notes LOS ANGELES, May 21, 2024 (GLOBE NEWSWIRE) -- BlackLine, Inc. (Nasdaq: BL), today announced that it intends to offer, subject to market conditions and other factors, $500,000,000 aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). BlackLine also intends to grant the initial purchaser of the notes a 13-day option to purchase...
Tejas Networks Ltd: 5 directors
Seven Directors at Tejas Networks Ltd sold 17,657 shares at between 1,145.102INR and 1,224.455INR. The significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's director...
BW Energy: Invitation to Q1 2024 results presentation 24 May
BW Energy: Invitation to Q1 2024 results presentation 24 May BW Energy: Invitation to Q1 2024 results presentation 24 May BW Energy will release its first quarter 2024 results on Friday 24 May at 07:30 CEST. A conference call followed by Q&A will be hosted by CEO Carl K. Arnet, CFO Knut R. Sæthre and COO Lin G. Espey the same day at 14:00 CEST. You can follow the presentation via webcast with supporting slides, available on: Viewer Registration • Q1 2024 (webcast.no) Call-in information Participants dial in numbers: DK: SE: NO: UK: 9 US: Singapore: 65...
KANZHUN LIMITED Announces First Quarter 2024 Financial Results
KANZHUN LIMITED Announces First Quarter 2024 Financial Results BEIJING, May 21, 2024 (GLOBE NEWSWIRE) -- KANZHUN LIMITED (“BOSS Zhipin” or the “Company”) (Nasdaq: BZ; HKEX: 2076), a leading online recruitment platform in China, today announced its unaudited financial results for the quarter ended March 31, 2024. First Quarter 2024 Highlights Revenues for the first quarter of 2024 were RMB1,703.8 million (US$236.0 million), an increase of 33.4% from RMB1,277.5 million for the same quarter of 2023.Calculated cash billings1 for the first quarter of 2024 were RMB2,050.7 million (US$284.0 mi...
ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Ebl...
ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International Conference Translational data presented during a late-breaker poster session from a head-to-head study of eblasakimab and dupilumab in a human tissue model of COPD indicates that eblasakimab performed better than dupilumab in improving airway function and enhancing bronchodilation at the same concentrations Results support further investigation of eblasakimab as a potential therapeutic option for COPD with potentially more effective blockade of Type-2 mediate...
Exscientia Business Update for First Quarter 2024
OXFORD, U.K.--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI): Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the first quarter 2024, are summarised below. Exscientia will host a conference call Tuesday, May 21 at 1:30 p.m. BST / 8:30 a.m. EDT. “With the ramp up of activities at our automation lab, we are beginning to see the transformative power of fully integrating AI drug design with the sheer capacity of comprehensive robotic automation across the entire experimentation cycle,” said Dr. David Hallett, interim Chief Executive...
ECARX-Powered Lynk & Co. 07 EM-P Sedan Began Deliveries in China
ECARX-Powered Lynk & Co. 07 EM-P Sedan Began Deliveries in China SHANGHAI, China, May 21, 2024 (GLOBE NEWSWIRE) -- ECARX Holdings Inc. (Nasdaq: ECX) (“ECARX” or the “Company”), a global mobility technology company, today congratulated Lynk & Co on the first deliveries of the Lynk & Co 07 EM-P sedan, which is integrated with ECARX’s full-stack solution for digital cockpit and ADAS including Antora® 1000 Pro, Skyland Pro, and Flyme Auto. The EM-P 07 began deliveries on May 17, 2024. The Lynk & Co 07 EM-P was officially unveiled at the Beijing Auto Show 2024 in April, where it attracted i...
LAVA Provides Business Updates and Reports First Quarter 2024 Financia...
LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results LAVA-1207 dose escalation progressing in Phase 1/2a trial in prostate cancer, with pembrolizumab combination expected to begin in Q2 2024Received $7.0 million clinical development milestone from Pfizer for PF-08046052 (formerly LAVA-1223) in Phase 1LAVA-1266 on track for Q2 2024 IND submissionStrong balance sheet with cash of $94.6 million supports runway into 2026 UTRECHT, The Netherlands and PHILADELPHIA, May 21, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncolog...
Tecnoglass to Attend the B. Riley Securities 24th Annual Institutional...
Tecnoglass to Attend the B. Riley Securities 24th Annual Institutional Investor Conference Miami, FL, May 21, 2024 (GLOBE NEWSWIRE) -- Tecnoglass, Inc. (NYSE: TGLS) ("Tecnoglass" or the "Company"), a leading producer of high-end aluminum and vinyl windows and architectural glass for the global residential and commercial end markets, today announced that the Company will attend the B. Riley Securities 24th Annual Institutional Investor Conference in Beverly Hills, CA on Thursday, May 23, 2024. About Tecnoglass Tecnoglass Inc. is a leading producer of high-end aluminum and vinyl windo...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.